Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
Adriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experien...
Saved in:
Main Authors: | Hironari Tamiya, Hideaki Sabe, Katsunari Yamashita, Yoshinori Imura, Toru Wakamatsu, Satoshi Takenaka |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Orthopedics |
Online Access: | http://dx.doi.org/10.1155/2020/8873185 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma
by: Hideaki Sabe, et al.
Published: (2021-01-01) -
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01) -
In-situ recurrence of cardiac myxoid liposarcoma after surgery
by: Zhen Wang, et al.
Published: (2025-02-01) -
A Case of Recurrent Mesocolon Myxoid Liposarcoma and Review of the Literature
by: Amar M. Eltweri, et al.
Published: (2013-01-01) -
Myxoid Liposarcoma of the Greater Omentum. Case Report and Literature Review
by: Alexander Marchena Rodríguez, et al.
Published: (2020-08-01)